Nymox Pharmaceutical annual r&d spending
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Nymox Pharmaceutical R&D Spending Growth & History (NYMXF)
Nymox Pharmaceutical's r&d spending was $3.3M for fiscal 2024.
View full Nymox Pharmaceutical company overviewNymox Pharmaceutical annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | $3.3M | −$714,000 | −17.88% |
| 2023 | 2023-12-31 | $4.0M | $221,000 | +5.86% |
| 2022 | 2022-12-31 | $3.8M | −$2.9M | −43.33% |
| 2021 | 2021-12-31 | $6.7M | −$1.5M | −18.00% |
| 2020 | 2020-12-31 | $8.1M | $743,000 | +10.07% |
| 2019 | 2019-12-31 | $7.4M | $700,000 | +10.48% |
| 2018 | 2018-12-31 | $6.7M | −$1.2M | −15.20% |
| 2017 | 2017-12-31 | $7.9M | $1.1M | +15.83% |
| 2016 | 2016-12-31 | $6.8M | −$1.9M | −21.41% |
| 2015 | 2015-12-31 | $8.7M | — | — |
Nymox Pharmaceutical quarterly r&d spending
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q3.24
Q4.24
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q4 2024 | 2024-12-31 | $624,000 | −$1.4M | −69.09% |
| Q3 2024 | 2024-09-30 | $511,000 | −$150,000 | −22.69% |
| Q4 2023 | 2023-12-31 | $2.0M | — | — |
| Q3 2023 | 2023-09-30 | $661,000 | −$231,000 | −25.90% |
| Q2 2023 | 2023-06-30 | $594,000 | −$216,000 | −26.67% |
| Q1 2023 | 2023-03-31 | $720,000 | −$3.6M | −83.39% |
| Q3 2022 | 2022-09-30 | $892,000 | −$947,000 | −51.50% |
| Q2 2022 | 2022-06-30 | $810,000 | −$1.3M | −60.83% |
| Q1 2022 | 2022-03-31 | $4.3M | $2.9M | +204.14% |
| Q4 2021 | 2021-12-31 | $1.3M | $152,000 | +12.95% |
| Q3 2021 | 2021-09-30 | $1.8M | −$1.4M | −43.15% |
| Q2 2021 | 2021-06-30 | $2.1M | −$88,000 | −4.08% |
| Q1 2021 | 2021-03-31 | $1.4M | −$130,000 | −8.36% |
| Q4 2020 | 2020-12-31 | $1.2M | −$630,000 | −34.92% |
| Q3 2020 | 2020-09-30 | $3.2M | $1.7M | +114.52% |
| Q2 2020 | 2020-06-30 | $2.2M | −$180,000 | −7.71% |
| Q1 2020 | 2020-03-31 | $1.6M | −$174,000 | −10.06% |
| Q4 2019 | 2019-12-31 | $1.8M | $287,000 | +18.92% |
| Q3 2019 | 2019-09-30 | $1.5M | −$146,000 | −8.83% |
| Q2 2019 | 2019-06-30 | $2.3M | $787,000 | +50.81% |
| Q1 2019 | 2019-03-31 | $1.7M | −$228,000 | −11.65% |
| Q4 2018 | 2018-12-31 | $1.5M | −$943,000 | −38.33% |
| Q3 2018 | 2018-09-30 | $1.7M | −$499,000 | −23.18% |
| Q2 2018 | 2018-06-30 | $1.5M | −$36,000 | −2.27% |
| Q1 2018 | 2018-03-31 | $2.0M | $281,000 | +16.77% |
| Q4 2017 | 2017-12-31 | $2.5M | — | — |
| Q3 2017 | 2017-09-30 | $2.2M | — | — |
| Q2 2017 | 2017-06-30 | $1.6M | — | — |
| Q1 2017 | 2017-03-31 | $1.7M | — | — |
Nymox Pharmaceutical r&d spending trends
Over the last five fiscal years, Nymox Pharmaceutical's r&d spending decreased from $7.4M to $3.3M, a change of −$4.1M. The latest reported quarter, Q4 2024, shows $624,000.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nymox Pharmaceutical source filings ↗